Literature DB >> 20951430

Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance.

Wanlong Ma1, Hagop Kantarjian, Xi Zhang, Xiuiang Wang, Zeev Estrov, Susan O'Brien, Maher Albitar.   

Abstract

The ubiquitin-proteasome system (UPS) plays a major role in the homeostasis of cellular protein. We demonstrate that each of the major hematologic diseases (AML, ALL, and MDS) has a specific and different plasma profile of UPS protein and enzymatic activities. While high levels of proteasome and ubiquitin proteins and enzymatic activities are detected in the plasma samples from patients, normalizing enzymatic activities, show that each proteasome has lower enzymatic activities in these diseases as compared with normal controls. Proteasome protein levels in AML are strong predictor of survival independently of cytogenetics, performance status and age. The Ch-L activity when normalized to the level of proteasome protein show significant negative correlation with survival in ALL.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20951430      PMCID: PMC4051750          DOI: 10.1016/j.leukres.2010.09.009

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  25 in total

1.  Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma.

Authors:  Maha Ahmed; Francis Giles; Youngson Joe; Donna M Weber; Iman Jilani; Taghi Manshouri; Sergio Giralt; Marcos De Lima; Michael Keating; Maher Albitar
Journal:  Eur J Haematol       Date:  2003-09       Impact factor: 2.997

2.  Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies.

Authors:  T Lavabre-Bertrand; L Henry; S Carillo; I Guiraud; A Ouali; D Dutaud; L Aubry; J F Rossi; J P Bureau
Journal:  Cancer       Date:  2001-11-15       Impact factor: 6.860

3.  Alveolar extracellular 20S proteasome in patients with acute respiratory distress syndrome.

Authors:  Stephan Urs Sixt; Michael Adamzik; Daniel Spyrka; Boris Saul; Jan Hakenbeck; Jeremias Wohlschlaeger; Ulrich Costabel; Alexander Kloss; Jan Giesebrecht; Burkhardt Dahlmann; Jürgen Peters
Journal:  Am J Respir Crit Care Med       Date:  2009-03-12       Impact factor: 21.405

4.  Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.

Authors:  Wanlong Ma; Hagop Kantarjian; Benjamin Bekele; Amber C Donahue; Xi Zhang; Zhong J Zhang; Susan O'Brien; Elihu Estey; Zeev Estrov; Jorge Cortes; Michael Keating; Francis Giles; Maher Albitar
Journal:  Clin Cancer Res       Date:  2009-05-19       Impact factor: 12.531

5.  Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance.

Authors:  Taghi Manshouri; Kim-anh Do; Xuemei Wang; Francis J Giles; Susan M O'Brien; Helen Saffer; Deborah Thomas; Iman Jilani; Hagop M Kantarjian; Michael J Keating; Maher Albitar
Journal:  Blood       Date:  2002-11-21       Impact factor: 22.113

6.  Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis.

Authors:  L Henry; T Lavabre-Bertrand; L Vercambre; J Ramos; S Carillo; I Guiraud; P Pouderoux; M Bismuth; J-C Valats; C Demattei; Y Duny; I Chaze; N Funakoshi; J P Bureau; J-P Daurès; P Blanc
Journal:  Gut       Date:  2009-02-06       Impact factor: 23.059

7.  Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia.

Authors:  Wanlong Ma; Hagop Kantarjian; Susan O'Brien; Iman Jilani; Xi Zhang; Zeev Estrov; Alessandra Ferrajoli; Michael Keating; Francis Giles; Maher Albitar
Journal:  Cancer       Date:  2008-03-15       Impact factor: 6.860

8.  Clinical correlation of circulating heat shock protein 70 in acute leukemia.

Authors:  Chen-Hsiung Yeh; Richard Tseng; Alison Hannah; Zeev Estrov; Elihu Estey; Hagop Kantarjian; Maher Albitar
Journal:  Leuk Res       Date:  2009-10-01       Impact factor: 3.156

9.  Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA.

Authors:  I Jilani; E Estey; T Manshuri; M Caligiuri; M Keating; F Giles; D Thomas; H Kantarjian; M Albitar
Journal:  Leukemia       Date:  2003-01       Impact factor: 11.528

10.  An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation.

Authors:  Iman Jilani; Hagop Kantarjian; Homan Faraji; Mercedes Gorre; Jorge Cortes; Oliver Ottmann; Kapil Bhalla; Susan O'Brien; Francis Giles; Maher Albitar
Journal:  Leuk Res       Date:  2007-12-26       Impact factor: 3.156

View more
  5 in total

1.  Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors.

Authors:  Dominika Hempel; Marek Z Wojtukiewicz; Leszek Kozłowski; Jacek Romatowski; Halina Ostrowska
Journal:  Tumour Biol       Date:  2011-05-25

2.  The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.

Authors:  Cedric Dos Santos; Tinisha McDonald; Yin Wei Ho; Hongjun Liu; Allen Lin; Stephen J Forman; Ya-Huei Kuo; Ravi Bhatia
Journal:  Blood       Date:  2013-07-29       Impact factor: 22.113

3.  SPR imaging biosensor for the 20S proteasome: sensor development and application to measurement of proteasomes in human blood plasma.

Authors:  Ewa Gorodkiewicz; Halina Ostrowska; Anna Sankiewicz
Journal:  Mikrochim Acta       Date:  2011-07-24       Impact factor: 5.833

Review 4.  The role of the proteasome in AML.

Authors:  C M Csizmar; D-H Kim; Z Sachs
Journal:  Blood Cancer J       Date:  2016-12-02       Impact factor: 11.037

5.  Loss of FBXO9 Enhances Proteasome Activity and Promotes Aggressiveness in Acute Myeloid Leukemia.

Authors:  R Willow Hynes-Smith; Samantha A Swenson; Heather Vahle; Karli J Wittorf; Mika Caplan; Catalina Amador; R Katherine Hyde; Shannon M Buckley
Journal:  Cancers (Basel)       Date:  2019-11-03       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.